Chemistry:Levonorgestrel cyclobutylcarboxylate
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | HRP-001; HRP001; Levonorgestrel cyclobutyl-carboxylate; Levonorgestrel cyclobutanecarboxylate; Levonorgestrel 17β-cyclobutylcarboxylate; 17α-Ethynyl-18-methyl-19-nortestosterone 17β-cyclobutylcarboxylate; 17α-Ethynyl-18-methylestr-4-en-17β-ol-3-one 17β-cyclobutylcarboxylate; 13-Ethyl-17α-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one cyclobutanecarboxylate |
| Routes of administration | Intramuscular injection |
| Drug class | Progestogen; Progestin; Progestogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C26H34O3 |
| Molar mass | 394.555 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Levonorgestrel cyclobutylcarboxylate (or levonorgestrel 17β-cyclobutylcarboxylate; developmental code name HRP-001) is a progestin and a progestogen ester which was studied for potential use as an injectable hormonal contraceptive but was never marketed.[1][2][3][4][5][6][7][8][9][10] It was developed by the World Health Organization's Special Programme on Human Reproduction in the 1980s.[1][2][9] Analogues of levonorgestrel cyclobutylcarboxylate include levonorgestrel butanoate (HRP-002) and levonorgestrel cyclopropylcarboxylate (HRP-003).[1][2][3]
See also
- List of progestogen esters § Esters of 19-nortestosterone derivatives
- Progestogen-only injectable contraceptive
References
- ↑ 1.0 1.1 1.2 "Carl Djerassi and the World Health Organisation special programme of research in human reproduction.". Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology 8 (1): 10–13. 2011. http://www.kup.at/kup/pdf/10163.pdf.
- ↑ 2.0 2.1 2.2 "Long-acting hormonal contraceptives for women". The Journal of Steroid Biochemistry and Molecular Biology 40 (4–6): 697–704. 1991. doi:10.1016/0960-0760(91)90293-E. PMID 1958567.
- ↑ 3.0 3.1 "Long-acting injectable hormonal dosage forms for contraception". Pharmaceutical Research 32 (7): 2180–2191. July 2015. doi:10.1007/s11095-015-1686-2. PMID 25899076.
- ↑ "Trends in Hormonal Contraception". Female Contraception. 1988. pp. 109–121. doi:10.1007/978-3-642-73790-9_9. ISBN 978-3-642-73792-3.
- ↑ "Systemic hormonal contraception by non-oral routes". Contraception: Science and Practice. Elsevier Science. 22 October 2013. pp. 112–. ISBN 978-1-4831-6366-6. https://books.google.com/books?id=Ug3-BAAAQBAJ&pg=PA112.
- ↑ The Contraception Sourcebook. McGraw Hill Professional. 4 December 2001. p. 133. ISBN 978-0-07-139945-6. https://books.google.com/books?id=HWoWwGwlEcUC.
- ↑ "Development of Levonorgestrel Esters as Long-Acting Injectable Contraceptives". Long-Acting Contraceptive Delivery Systems: Proceedings of an International Workshop on Long-Acting Contraceptive Delivery Systems, May 31-June 3, 1983, New Orleans, Louisiana. Harper & Row Pub.. 1984. p. 196. ISBN 978-0-06-142905-7. https://books.google.com/books?id=QKtsAAAAMAAJ.
- ↑ Fertility regulation today and tomorrow. Raven Press. 1987. p. 132. ISBN 978-0-88167-180-3. https://books.google.com/books?id=-GJqAAAAMAAJ.
- ↑ 9.0 9.1 Recent advances in fertility control: proceedings of the 1st International Symposium on Recent Advances in Fertility Control, Tokyo, November 8, 1986. Excerpta Medica. 1987. p. 67. ISBN 978-90-219-1638-5. https://books.google.com/books?id=X6tsAAAAMAAJ.
- ↑ Contraception: newer pharmacological agents, devices, and delivery systems. M. Dekker. 1992. p. 62. ISBN 978-0-8247-8700-4. https://books.google.com/books?id=L5NsAAAAMAAJ.
 |  |
